IR Information
IR Information
News Release
News release
-
2025.03.26
Announcement of the renewal of the business partnership agreement with Sino Biopharmaceutical Limited
(250KB)
-
2025.03.21
Notice of Agreement of License Term Sheet for PC-SOD in Europe
(208KB)
-
2025.03.18
Announcement of a presentation at the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025)
(381KB)
-
2025.03.18
Announcement of Membership in the Academia-based Bio/Healthcare Venture Association and Appointment of Our CEO as a Director of the Association.
(240KB)
-
2025.03.18
Announcement of Headquarters Relocation
(355KB)
Financial Information
Disclosure
Financial Results
| 21st Fiscal Period (Results for March 2023) | |
|---|---|
| Net sales (Thousands of yen) | 15,271 |
| Operating income (thousand yen) | 81,000 |
| Net income (thousand yen) | 70,254 |
| Net assets (Thousands of yen) | 4,002,480 |
| Total assets (Thousands of yen) | 4,214,922 |
| Equity ratio (%) | 94.9 |
Business Report
Business report
21th Term
Business Overview
(485KB)
20th Term
Business Overview
(568KB)
19th Term
Business Overview
(595KB)
18th Term
Business Overview
(527KB)
17th Term
Business Overview
(521KB)
